AF is also getting pretty bipolar on CLDX. His latest or near latest article points out CLDX might be overvalued, then he claims it's not overvalued. Then he claims at ASCO their results "rock." Stock has been falling since. Moreover, the CLDX CEO recently admitted phase II Stat. Sig. results in recurrent GBM could possibly be affected by random selection bias in favor of the treatment group. Again, the stock has been falling significantly. Their phase III newly diagnosed GBM trial is fully enrolled and 1st IA results could be released any day. Nobody has been expecting huge improvements, but under further scrutiny, I think people are now weighing anything from a small victory to a possible early termination for futility. Meanwhile he has moved from calling LP misleading, and a poor spokesperson, to calling DR. MB misleading. He just keeps sinking lower, oh wait, that's impossible.